Fluticasone / Formoterol: 3 agencies, 2011–2019
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused fluticasone / formoterol: all 4 decisive outcomes across 2 agencies were positive or positive with restrictions.
Assessment has run over 7.8 years, from 5 Aug 2011 at AWMSG (Wales) to 10 Jun 2019 at SMC (Scotland).
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for fluticasone / formoterol at all.
Nothing has been added since 2019; on this evidence the file is dormant.
6 distinct indication wordings are recorded for fluticasone / formoterol by the agencies that label one in English (AWMSG and SMC).
AWMSG (Wales) was first to assess fluticasone / formoterol, on 5 Aug 2011; HAS (France) did not open a file until 26 Jun 2013 — a moderate spread of 1.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 8 dated records fall in 2018 alone.
3 of the 3 agencies here assessed fluticasone / formoterol more than once, SMC (Scotland) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 3 of the 18 agencies here have assessed fluticasone / formoterol.
The full ledger for fluticasone / formoterol reads 4 recommended, 3 not assessed and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 10 Jun 2019 | For the licence extension of low strength flutiform (50/5 µg) in children aged 5 to <12 years. This fixed-dose combination of fluticasone propionate and formoterol fumara… | accepted | source |
| SMC (Scotland) | 11 Jun 2018 | Indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: • For patient… | accepted | source |
| AWMSG (Wales) | 28 Feb 2018 | Regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a LABA) is appropriate… | outside AWMSG criteria | source |
| AWMSG (Wales) | 7 Feb 2018 | Regular treatment of asthma in adults and adolescents over 12 years where the use of a combination product (an inhaled c… | outside AWMSG criteria | source |
| HAS (France) | 26 Jun 2013 | Listing (Transparency Committee) | ASMR V | source |
3 further decisions for fluticasone / formoterol, across 3 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- fluticasone — same ATC class R01A — Nasal preparations
- azelastine / fluticasone — same ATC class R01A — Nasal preparations
- ciclesonide — same ATC class R01A — Nasal preparations
- mometasone — same ATC class R01A — Nasal preparations
- fluticasone / umeclidinium / vilanterol — same ATC class R01A — Nasal preparations
- azelastine — same ATC class R01A — Nasal preparations
Coverage: 8 decisions for fluticasone / formoterol from 3 agencies, 2011 to 2019. Data to 7 Sep 2026. ATC class R01A — Nasal preparations. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.